DSM Biologics said that, by increasing the cell density and optimising the conditions for protein production of a culture, its proprietary XD Technology offers a simple, elegant solution to substantially increase titers without changing the cell line or process media.
DSM Biologics claimed that the technology has broad applicability and benefits to mammalian cell systems and across various target production molecules including monoclonal antibodies and recombinant proteins.
The improved performance has been achieved using off-the-shelf, chemically-defined media within a two week culture. Progress is underway for scale-up to the next level with results anticipated later in 2010.
Jeremy Caudill, vice president of sales and business development at DSM, said: “The results from DSM’s proprietary XD technology demonstrate a paradigm shift in biologics drug manufacturing. Companies can now substantially shrink their bioreactor size requirements by 5-10 fold, reducing the Capex required for building a new plant and ultimately reducing overall cost of goods.”
Rolf Douwenga, vice president of Global Technology, said “We are excited about the robustness of the scale-up to 50L scale. The data proves again that the XD technology is very consistent in scalability independent of the cell lines or types of recombinant proteins we have tested.”